Paul Feuerstadt, MD: The Future of RBX2660

Published on: 

Pauk Feuerstadt, MD, discusses some future applications of RBX2660.

With RBX2660 (Rebyota) for the prevention of recurrent Clostridioides difficile infections (rCDI) in adult patients who completed a primary antibiotic series now approved by the US Food and Drug Administration, stakeholders can begin to look at what is next for live microbiota therapeutics.

Whether that is the next approval for a similar drug or testing a product like RBX2660 for other diseases like inflammatory bowel disease (IBD) will shape out in the coming years.

In an interview with HCPLive®, Paul Feuerstadt, MD, Assistant Clinical Professor of Medicine, Yale School of Medicine, discussed the future of RBX2660 and how it could help revolutionize CDI care.

“This is such an exciting time, patients are really going to benefit,” Feuerstadt said. “The fact that the FDA has chosen to approve a product for microbiota restoration therapy really changes the game.”

Feuerstadt went on to say he envisions a situation where the product is tested and studied for safety and efficacy treating patients with IBD.

The treatment, developed by Ferring Pharmaceuticals, is prepared from stool donated by qualified individuals and administered rectally as a single dose. RBX2660 is a standardized, stabilized, investigational microbiota-based live therapeutic.

While this is the first approval for such a product, it is likely that it won’t be the last as at least 1 more live microbiota therapeutic has a Prescription Drug User Fee Act (PDUFA) date set for the first half of 2023.